• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 25th March 2010

How Fair? Competition in the NHS

Competition within the NHS for non-emergency hospital care no longer adjusts for non-discretionary costs unique to independent providers. Should it? Jon Sussex   Since 2002, the UK government has actively promoted competition for the provision of non-emergency hospital care to…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Jon Sussex

Competition within the NHS for non-emergency hospital care no longer adjusts for non-discretionary costs unique to independent providers. Should it?

Jon Sussex Jon Sussex

 

Since 2002, the UK government has actively promoted competition for the provision of non-emergency hospital care to publicly-funded patients in England.  In contrast to the health care competition introduced into the National Health Service under the Conservative government in the early 1990s, however, the purpose is not to directly affect the price of health care. Rather, it is intended to improve health care access and quality for patients. Prices now are fixed by the government, not arrived at through local trading.

Much more emphasis has been given since 2002 to competition between NHS hospitals and independent hospitals and Independent Sector Treatment Centres (ISTCs).  In a recent OHE Briefing, Jon Sussex clearly and thoroughly examines non-discretionary cost differences between public and independent providers that may have a serious impact on the effectiveness of such competition.  He identifies four key cost differences between the ISTCs and NHS hospitals, summarized in the box.

The policy of competition from the independent sector has met barriers along the way. Potential NHS commissioners of hospital care remain reluctant to increase reliance on the independent sector. The implementation of ISTCs serving NHS patients was only achieved advantageous financial terms offered by the government to stimulate market entry.  No further such ISTC procurements are planned.  As a result, the extent of independent sector competition with NHS hospitals will increasingly depend on attracting patients under the policy of free choice of hospital for non-emergency care.  Non-discretionary cost differences that leave the ISTCs at a cost disadvantage in the order of 12-15% compared to NHS hospitals then becomes an issue. Although this may not be enough to cause a significant number of ISTCs to withdraw from the market, it is not entirely clear what effect such uneven competition will have.  Will ISTCs remain competitive enough to continue to encourage efficiency and improve quality in the NHS?

Should measures be taken specifically to ensure ‘fairness’? If so, what are the options?  One might be to compensate by increasing funding by x% for independent sector hospitals and treatment centres.  Other options include measures to reduce or remove the causes of non-discretionary cost difference by changing pension schemes, corporation taxes and VAT arrangements.  Since such changes could have implications well outside the health care sector, the answers are neither clear nor simple.

Download Sussex, J. (2009) How fair? Competition between independent and NHS providers to supply non-emergency hospital care to NHS patient in England.  OHE Briefing. (50).  London: Office of Health Economics.

  • Health Care Systems
  • Briefing

Related News

  • News
  • May 2019

OHE Lunchtime Seminar: Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures

Read more
  • News
  • May 2019

OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing

Read more
  • News
  • April 2019

Quality of Life and Rare Disease: Lessons from Spinal Muscular Atrophy

Read more
  • News
  • November 2018

Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!